Article
Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.
MMWR. Morbidity and mortality weekly report - 10 Oct 2024
Gigante Crystal M, Takakuwa Jade, McGrath Daisy, Kling Chantal, Smith Todd G, Peng Mengfei, Wilkins Kimberly, Garrigues Jacob M, Holly Taylor, Barbian Hannah, Kittner Alyse, Haydel Danielle, Ortega Emma, Richardson Gillian, Hand Julie, Hacker Jill K, Espinosa Alex, Haw Monica, Kath Chantha, Bielby Meilan, Short Kirstin, Johnson Kimberly, De La Cruz Nelson, Davidson Whitni, Hughes Christine, Green Nicole M, Baird Nicolle, Rao Agam K, Hutson Christina L
Abstract excerpt
The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public...
Topics
Join the communities discussing this publication.